JP2017512811A - 非晶質ソホスブビルを含む固体組成物 - Google Patents

非晶質ソホスブビルを含む固体組成物 Download PDF

Info

Publication number
JP2017512811A
JP2017512811A JP2016560461A JP2016560461A JP2017512811A JP 2017512811 A JP2017512811 A JP 2017512811A JP 2016560461 A JP2016560461 A JP 2016560461A JP 2016560461 A JP2016560461 A JP 2016560461A JP 2017512811 A JP2017512811 A JP 2017512811A
Authority
JP
Japan
Prior art keywords
sofosbuvir
weight
solid composition
matrix compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016560461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512811A5 (enExample
Inventor
マーティン，ノルウェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JP2017512811A publication Critical patent/JP2017512811A/ja
Publication of JP2017512811A5 publication Critical patent/JP2017512811A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016560461A 2014-04-03 2015-04-02 非晶質ソホスブビルを含む固体組成物 Ceased JP2017512811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163434.5 2014-04-03
EP14163434 2014-04-03
PCT/EP2015/057411 WO2015150561A2 (en) 2014-04-03 2015-04-02 Solid composition comprising amorphous sofosbuvir

Publications (2)

Publication Number Publication Date
JP2017512811A true JP2017512811A (ja) 2017-05-25
JP2017512811A5 JP2017512811A5 (enExample) 2019-11-14

Family

ID=50397065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560461A Ceased JP2017512811A (ja) 2014-04-03 2015-04-02 非晶質ソホスブビルを含む固体組成物

Country Status (10)

Country Link
US (2) US10493089B2 (enExample)
EP (1) EP3125868A2 (enExample)
JP (1) JP2017512811A (enExample)
KR (1) KR20160142342A (enExample)
CN (1) CN106163529A (enExample)
AU (1) AU2015239018A1 (enExample)
CA (1) CA2943574A1 (enExample)
MX (2) MX2016012934A (enExample)
RU (1) RU2016142819A (enExample)
WO (1) WO2015150561A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020071539A1 (ja) 2018-10-05 2020-04-09 富士化学工業株式会社 多孔性シリカ粒子組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214553B2 (en) 2014-06-13 2019-02-26 Teva Pharmaceuticals International Gmbh Solid state forms of sofosbuvir
WO2016038542A2 (en) * 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
CZ2015443A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
EP3359199A1 (en) * 2015-10-07 2018-08-15 Sandoz AG Solid pharmaceutical composition comprising amorphous sofosbuvir
CZ2016257A3 (cs) * 2016-05-05 2017-11-15 Zentiva, K.S. Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace
CN106083963A (zh) * 2016-06-08 2016-11-09 上海现代制药海门有限公司 一种索非布韦晶型6的制备方法
BR112019002729A2 (pt) * 2016-08-12 2019-05-14 Sandoz Ag composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
WO2018078536A1 (en) 2016-10-26 2018-05-03 Lupin Limited Stable solid dispersion of sofosbuvir and process for preparation thereof
CN108210509A (zh) * 2016-12-13 2018-06-29 南京圣和药业股份有限公司 新的核苷氨基磷酸脂化合物的组合物及其制备方法
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
CN111040010A (zh) * 2019-12-23 2020-04-21 上海红蓝医药科技有限公司 一种索非布韦中间体的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527477A (ja) * 2009-05-20 2012-11-08 ギリアド ファーマセット エルエルシー Ｎ−［（２’ｒ）−２’−デオキシ−２’−フルオロ−２’−メチル−ｐ−フェニル−５’−ウリジリル］−ｌ−アラニン１−メチルエチルエステルおよびその製造のためのプロセス
WO2013101500A1 (en) * 2011-12-30 2013-07-04 Chevron U.S.A. Inc. Process, method, and system for removing heavy metals from fluids
JP2015503560A (ja) * 2011-12-29 2015-02-02 アッヴィ・インコーポレイテッド Ｈｃｖ阻害剤を含む固体組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513964A (en) * 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
CN1200262C (zh) 2003-01-10 2005-05-04 清华大学 测量粉末吸附气体量的方法和设备
WO2010017965A2 (en) 2008-08-11 2010-02-18 Merck Serono S.A. SOLID LIPID MICROCAPSULES CONTAINING hGH
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
EP3650014B1 (en) * 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527477A (ja) * 2009-05-20 2012-11-08 ギリアド ファーマセット エルエルシー Ｎ−［（２’ｒ）−２’−デオキシ−２’−フルオロ−２’−メチル−ｐ−フェニル−５’−ウリジリル］−ｌ−アラニン１−メチルエチルエステルおよびその製造のためのプロセス
JP2015503560A (ja) * 2011-12-29 2015-02-02 アッヴィ・インコーポレイテッド Ｈｃｖ阻害剤を含む固体組成物
WO2013101500A1 (en) * 2011-12-30 2013-07-04 Chevron U.S.A. Inc. Process, method, and system for removing heavy metals from fluids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020071539A1 (ja) 2018-10-05 2020-04-09 富士化学工業株式会社 多孔性シリカ粒子組成物
US12116285B2 (en) 2018-10-05 2024-10-15 Fuji Chemical Industries Co., Ltd. Porous silica particle composition

Also Published As

Publication number Publication date
WO2015150561A3 (en) 2016-01-28
MX2016012934A (es) 2016-12-07
US10493089B2 (en) 2019-12-03
EP3125868A2 (en) 2017-02-08
RU2016142819A (ru) 2018-05-10
MX2019009842A (es) 2019-10-22
US20170100422A1 (en) 2017-04-13
US20190381085A1 (en) 2019-12-19
KR20160142342A (ko) 2016-12-12
CN106163529A (zh) 2016-11-23
AU2015239018A1 (en) 2016-10-13
RU2016142819A3 (enExample) 2018-05-10
WO2015150561A2 (en) 2015-10-08
CA2943574A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
JP2017512811A (ja) 非晶質ソホスブビルを含む固体組成物
CN1630510A (zh) 药物形式的阿托伐他汀钙、其组合物和包含阿托伐他汀钙的药物配方
EP2068835A2 (en) Imatinib compositions
WO2017121806A1 (en) Pharmaceutical composition of selexipag
WO2017163170A1 (en) Pharmaceutical composition comprising apixaban
US20180271890A1 (en) Solid Pharmaceutical Composition Comprising Amorphous Sofosbuvir
JP2009527577A (ja) フルバスタチンナトリウム医薬組成物
PT2165702E (pt) Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
WO2017211779A1 (en) Pharmaceutical compositions of betrixaban maleate
JP2016512845A (ja) ソバプレビル錠剤
KR101446129B1 (ko) 프란루카스트-함유 고형 제제의 제조방법
KR20190038881A (ko) 무정형 소포스부비르를 포함하는 고체 제약 조성물
AU2007300071A1 (en) Atorvastatin pharmaceutical compositions
KR20080080230A (ko) 무수 올란자핀 ⅰ형의 경구 제형
KR20220077094A (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
WO2022049075A1 (en) Amorphous solid dispersion of darolutamide
KR100591786B1 (ko) 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
EA045511B1 (ru) Состав с афабицином, способ его получения и его применение
KR20080109463A (ko) 페노피브레이트 함유 신규 조성물
WO2019030387A1 (en) SOLID COMPOSITION COMPRISING AMORPHOUS SOFOSBUVIR AND AMORPHOUS DACLATASVIR

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191001

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191029

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20200225